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The carboxy-terminal 150 residues of the focal adhesion kinase (FAK) comprise the focal adhesion-
targeting sequence, which is responsible for its subcellular localization. The mechanism of focal
adhesion targeting has not been fully elucidated. We describe a mutational analysis of the focal
adhesion-targeting sequence of FAK to further examine the mechanism of focal adhesion targeting
and explore additional functions encoded by the carboxy-terminus of FAK. The results demon-
strate that paxillin binding is dispensable for focal adhesion targeting of FAK. Cell adhesion-
dependent tyrosine phosphorylation strictly correlated with the ability of mutants to target to
focal adhesions. Focal adhesion targeting was also a requirement for maximal FAK-dependent
tyrosine phosphorylation of paxillin and FAK-related nonkinase (FRNK)–dependent inhibition of
endogenous FAK function. However, there were additional requirements for these latter functions
because we identified mutants that target to focal adhesions, yet are defective for the induction of
paxillin phosphorylation or the dominant-negative function of FRNK. Furthermore, the paxillin-
binding activity of FRNK mutants did not correlate with their ability to inhibit FAK, suggesting
that FRNK has other targets in addition to paxillin.
INTRODUCTION
The focal adhesion kinase (FAK) is a cytoplasmic protein
tyrosine kinase (PTK) that is localized to focal adhesions
(Hanks et al., 1992; Schaller et al., 1992). FAK colocalizes with
transmembrane receptors for the extracellular matrix called
integrins. Engagement of integrins with their ligand induces
tyrosine phosphorylation and enzymatic activation of FAK
(Guan and Shalloway, 1992; Hanks et al., 1992; Kornberg et
al., 1992; Lipfert et al., 1992). Thus, FAK is involved in the
transmission of cytoplasmic signals after integrin-dependent
cell adhesion. FAK has been implicated in controlling sev-
eral integrin-dependent biological processes, including cell
spreading, migration, survival, and regulation of cell cycle
(Frisch and Francis, 1994; Ilic et al., 1995; Gilmore and Ro-
mer, 1996; Hungerford et al., 1996; Richardson and Parsons,
1996; Zhao et al., 1998).
The catalytic domain of FAK is centrally located and is
flanked by large amino- and carboxy-terminal noncatalytic
domains. The amino-terminal domain binds peptides, mim-
icking the carboxy terminus of the b1 integrin subunit in
vitro (Schaller et al., 1995), but this putative interaction is
dispensable for integrin-dependent tyrosine phosphoryla-
tion of FAK in vivo (Tahiliani et al., 1997; Shen and Schaller,
1999). The carboxy terminus contains binding sites for a
number of focal adhesion-associated proteins and signaling
molecules. The carboxy-terminal 150 amino acids of FAK
contain binding sites for both paxillin and talin (Turner and
Miller, 1994; Chen et al., 1995; Hildebrand et al., 1995). This
region of FAK is called the focal adhesion-targeting (FAT)
sequence and is responsible for directing FAK to its focal
adhesion location (Hildebrand et al., 1993). Between the
catalytic domain and FAT sequence of FAK there are two
proline-rich regions that serve as docking sites for the Src
homology (SH)3 domains of p130cas and GTPase-activating
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protein for Rho associated with FAK (GRAF) (Polte and
Hanks, 1995; Harte et al., 1996; Hildebrand et al., 1996). In
addition to these binding partners, there are two tyrosine
residues in FAK that can become phosphorylated to create
SH2 domain-binding sites (Schaller et al., 1994; Xing et al.,
1994; Calalb et al., 1995). The major site of autophosphory-
lation of FAK, tyrosine 397, lies to the amino-terminal side of
the catalytic domain and serves as a binding site for the SH2
domain of Src (Schaller et al., 1994; Xing et al., 1994). Inter-
estingly, there is a functional Src SH3 domain-binding site in
this vicinity that also contributes to the stability of the FAK/
Src complex (Thomas et al., 1998). When phosphorylated,
tyrosine 397 also functions as a docking site for the SH2
domains of other signaling molecules, including phosphati-
dylinositol 39-kinase and phospholipase Cg (Reiske et al.,
1999; Zhang et al., 1999). The SH2 domain of growth factor
receptor-binding protein 7 (Grb7) also binds to tyrosine-
phosphorylated FAK and may interact with phosphorylated
tyrosine 397 (Han and Guan, 1999). A tyrosine residue in the
carboxy-terminal domain of FAK, tyrosine 925, serves as a
growth factor receptor-binding protein 2 (Grb2)-binding site
when phosphorylated and is proposed to function in the acti-
vation of the Ras/mitogen-activated protein kinase pathway
(Schlaepfer et al., 1994; Schlaepfer and Hunter, 1996, 1997).
Cell adhesion kinase b (CAKb) (also known as Pyk2,
CADTK, RAFTK, and FAK2) is an FAK-related PTK (Avra-
ham et al., 1995; Lev et al., 1995; Sasaki et al., 1995; Herzog et
al., 1996; Yu et al., 1996). Like FAK, CAKb has large amino-
and carboxy-terminal domains flanking the central catalytic
domain and the two exhibit 45% overall amino acid identity.
The regions of greatest homology are the catalytic domain
(60% identity) and the FAT sequence of FAK (61% identity).
There is some evidence that CAKb can be regulated by
integrin-dependent cell adhesion, but the major stimuli that
induce tyrosine phosphorylation of CAKb are growth fac-
tors, neuropeptides, and other stimuli that elevate cytoplas-
mic calcium (Lev et al., 1995; Dikic et al., 1996; Li et al., 1996;
Yu et al., 1996; Hiregowdara et al., 1997; Schaller and Sasaki,
1997; Brinson et al., 1998). Although CAKb has been re-
ported to localize to focal adhesions, many reports describe
a diffuse cytoplasmic localization (Schaller and Sasaki, 1997;
Sieg et al., 1998; Zheng et al., 1998). However, the C-terminal
noncatalytic domain localizes to focal adhesions when ex-
pressed autonomously, demonstrating that CAKb does con-
tain a functional FAT sequence (Schaller and Sasaki, 1997;
Xiong et al., 1998). Interestingly, the carboxy-terminal non-
catalytic domains of FAK and CAKb have been described as
naturally occurring, autonomously expressed variants of
FAK and CAKb (Schaller et al., 1993; Xiong et al., 1998).
These variants have been called FAK-related nonkinase
(FRNK), CAKb-related nonkinase (CRNK), or Pyk2-related
nonkinase (PRNK). The differential expression of FAK and
FRNK is apparently regulated at the level of transcription
because the mRNAs encoding these two proteins arise from
two distinct promoters within the FAK gene (Nolan et al.,
1999). Presumably expression of CAKb and CRNK/PRNK
are regulated by a similar mechanism. Although the func-
tions of endogenous FRNK and CRNK/PRNK have not
been fully elucidated, both FRNK and CRNK have been
used experimentally as dominant-negative mutants to per-
turb signaling via endogenous, wild-type FAK and CAKb
(Richardson and Parsons, 1996; Li et al., 1999).
The carboxy-terminal FAT sequence of FAK is indispens-
able for its normal function in signal transduction (Shen and
Schaller, 1999). Deletion mutants that ablate targeting to
focal adhesions fail to become tyrosine phosphorylated in
response to integrin-dependent cell adhesion. Similarly,
these mutants fail to induce tyrosine phosphorylation of
focal adhesion-associated substrates. Therefore, either local-
ization to focal adhesions per se is a major prerequisite for
FAK function, or carboxy-terminal sequences have a second
role in addition to focal adhesion targeting that is important
for FAK function. Because a chimeric molecule in which the
FAT sequence of FAK is replaced by the focal adhesion-
targeting sequence of vinculin exhibits very similar proper-
ties to wild-type FAK, the former hypothesis is favored
(Shen and Schaller, 1999). These findings further underscore
the importance of focal adhesion targeting in FAK function,
yet the mechanism by which FAK localizes to focal adhe-
sions remains controversial. The carboxy-terminal 150 resi-
dues of FAK contains the FAT sequence and a binding site
for the focal adhesion-associated protein paxillin (Hilde-
brand et al., 1993, 1995). Deletion analysis has failed to
separate the sequences responsible for focal adhesion target-
ing and paxillin binding (Hildebrand et al., 1995). A number
of mutants of FAK that contain point mutations that disrupt
paxillin binding fail to localize to focal adhesions, suggest-
ing that paxillin binding is required for focal adhesion tar-
geting of FAK (Tachibana et al., 1995). This result is in
disaccord with reports of FAK variants that are unable to
bind paxillin yet correctly localize to focal adhesions
(Schaller et al., 1993; Hildebrand et al., 1995; Sieg et al., 1999).
Talin binding also has been proposed as the mechanism of
focal adhesion targeting because talin was reported to coim-
munoprecipitate with FAK, which efficiently targets to focal
adhesions, but not with CAKb, which does not (Zheng et al.,
1998). However, talin-binding activity does not strictly cor-
relate with the ability of FAK mutants to target to focal
adhesions (Hildebrand et al., 1993; Chen et al., 1995). To
further explore the mechanism of focal adhesion targeting of
FAK, and to examine whether the FAT sequence may per-
form other functions in addition to targeting, a further mu-
tational analysis was carried out.
Because the carboxy-terminal domains of FAK and CAKb
exhibit a number of common features, including paxillin bind-
ing and a functional FAT sequence (Salgia et al., 1996; Hire-
gowdara et al., 1997; Li and Earp, 1997; Schaller and Sasaki,
1997; Xiong et al., 1998), conserved residues were targeted for
mutagenesis. Seven mutants containing multiple alanine sub-
stitutions were engineered and analyzed. The results provide
additional evidence that paxillin-binding activity is dispens-
able for focal adhesion targeting of FAK. Cell adhesion-depen-
dent regulation of tyrosine phosphorylation of FAK strictly
correlated with the ability of FAK mutants to localize to focal
adhesions. Although focal adhesion targeting was required for
efficient FAK-dependent tyrosine phosphorylation of the focal
adhesion-associated protein paxillin and the ability of FRNK to
function as a dominant-negative mutant of FAK, some mutants
were defective for these functions despite correctly localizing to
focal adhesions. These results suggest that the carboxy-termi-
nus of FAK has other functions besides targeting FAK to focal
adhesions, that the mechanism of the dominant-negative action
of FRNK is not simply by displacing FAK from focal adhe-
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As previously described, chicken embryo (CE) cells were isolated
from day 9 embryos and maintained in DMEM 1 4% fetal bovine
serum 1 1% chick serum (Reynolds et al., 1989). NIH 3T3 cells were
maintained in DMEM 1 10% calf serum and 293 cells in DMEM/
F12 1 10% fetal bovine serum. For expression in CE cells, FAK and
FRNK variants were subcloned into the replication competent,
avian retroviral vector called RCAS and cells transfected as previ-
ously described (Reynolds et al., 1989; Schaller et al., 1993). For
expression in mammalian cells, FAK variants were engineered as
green fluorescent protein (GFP) fusion proteins in the pEGFP-C3
vector (Clontech, Palo Alto, CA). The constructs were introduced
into NIH 3T3 and 293 cells by using Lipofectamine (Life Technolo-
gies, Gaithersburg, MD) according to the manufacturer’s recom-
mended protocol. For cell adhesion experiments, cells were
trypsinized, maintained in suspension, and plated onto fibronectin-
coated dishes as previously described (Shen and Schaller, 1999). In
some experiments cells were treated with 2 mM pervanadate for 30
min prior to lysis to inhibit cellular protein tyrosine phosphatases.
Molecular Biology
Mutations were engineered into the FAK cDNA by site-directed
mutagenesis with the Altered Sites kit (Promega, Madison, WI) and
mutants were identified by sequencing with a Sequenase kit (Am-
ersham, Piscataway, NJ). A segment of the FAK cDNA containing
the point mutation(s) was subcloned into other vectors for further
analysis of the properties of these mutants. For expression as a
glutathione-S-transferase (GST) fusion protein, the Nru I-EcoRI
fragment (nucleotides 2717–3248) or the NheI-EcoRI fragment (nu-
cleotides 2948–3248) was excised from the mutagenesis vector pAl-
ter and substituted for the corresponding fragment from GST-H-
FAK, which contains codons 765-1052 of wild-type FAK inserted
into the pGex2TK vector (Pharmacia, Piscataway, NJ) (Shen et al.,
1998). For expression as full-length FAK in CE cells, the mutations
were first rescued into an epitope-tagged, full-length FAK cDNA in
the pBluescript vector (Stratagene, La Jolla, CA) (Schaller et al.,
1993). This was achieved by amplifying the fragment of FAK con-
taining the point mutation(s) by polymerase chain reaction (PCR),
and then substituting either the Nru I/ClaI fragment (nucleotides
2717–3167 of FAK) or the NheI/ClaI fragment (nucleotides 2948–
3167 of FAK) of the reaction product for the corresponding fragment
of the epitope-tagged FAK. The KT3 epitope tag is fused in-frame
with the FAK sequences at the ClaI site. The mutated, tagged FAK
insert was then subcloned into the replication competent RCAS A
retroviral vector. For expression as FRNK constructs, the sequences
encoding FRNK were amplified by PCR with the mutated pAlter-
FAK plasmids as template. The two primers, one that annealed 59 of
the FRNK initiation codon and one that annealed in the multiple
cloning site of pAlter downstream of the termination codon, were
designed to contain SpeI sites. The amplification product was sub-
cloned into pBSX, a pBluescript derivative containing a SalI-XbaI
fragment from the RCAS A vector. The FRNK and the RCAS A
vector sequences were excised by using SalI and inserted into RCAS
A. For expression as a GFP fusion protein, the wild-type FAK cDNA
was cloned in-frame with the GFP-encoding sequences of
pEGFP-C3 (Clontech). Mutated FAK sequences were introduced
into this construct by substitution of the Nru I/SalI fragment of the
mutated FAK sequences in pAlter (extending from nucleotide 2717
of FAK into the multiple cloning site of pAlter) with the correspond-
ing Nru I/SalI fragment of pEGFP-FAK (extending from nucleotide
2717 of FAK into the multiple cloning site of pEGFP-C3). All of the
amplified sequences were completely sequenced to verify that no
unintended mutations were introduced during the procedure. DNA
was sequenced at the University of North Carolina-Chapel Hill
Automated DNA Sequencing Facility on a model 377 DNA Se-
quencer (Perkin Elmer-Cetus, Applied Biosystems Division, Nor-
walk, CT) by using the ABI PRISM Dye Terminator Cycle Sequenc-
ing Ready Reaction kit with AmpliTaq DNA Polymerase, FS (Perkin
Elmer-Cetus, Applied Biosystems Division).
Protein Analysis
Cells were lysed in modified RIPA buffer (Thomas et al., 1999),
Tx-RIPA buffer (Thomas et al., 1999), or IGEPAL lysis buffer (20 mM
Tris, pH 8.0, 137 mM NaCl, 1% IGEPAL detergent, 10% glycerol)
containing protease and phosphatase inhibitors as described
(Thomas et al., 1999). The protein concentration of lysates was
determined by using the bicinchoninic acid assay (Pierce, Rockford,
IL). Immunoprecipitations were typically performed by using 0.2–1
mg of cell lysate and 5–30 ml of polyclonal antiserum or 2 mg of
purified monoclonal antibody (mAb). After incubation on ice for 1 h
immune complexes were precipitated by using protein A Sepharose
(Sigma, St. Louis, MO) or anti-mouse agarose beads (Sigma). Im-
mune complexes were washed twice with lysis buffer, twice with
phosphate-buffered saline, and then eluted in sample buffer
(Laemmli, 1970). Subsequently, samples were analyzed by Western
blotting. Polyclonal antisera BC2 and BC4 and mAb 2A7 (generous
gifts of Dr. Tom Parsons, University of Virginia, Charlottesville, VA)
were used to recognize FAK. A polyclonal antiserum (Thomas et al.,
1999) and a commercial mAb (Transduction Labs, Lexington, KY)
were used for the analysis of paxillin. The mAb KT3 was used for
recognition of the epitope tag (MacArthur and Walter, 1984) and a
polyclonal antibody was used for detection of GST (Molecular
Probes, Eugene, OR). RC20 was used to detect phosphotyrosine
(Transduction Labs). Western blots were incubated with horserad-
ish peroxidase-conjugated secondary antibodies and processed for
enhanced chemiluminescence (Amersham).
In Vitro-Binding Assay
The expression of GST-FAK fusion proteins was induced by using
0.1 mM isopropyl-1-thio-b-d-galactopyranoside. Escherichia coli
were harvested, lysed by sonication, and the fusion proteins puri-
fied by using glutathione agarose beads (Sigma) as previously de-
scribed (Thomas et al., 1999). CE cell lysates prepared in IGEPAL
lysis buffer were precleared with 5 mg of GST. The supernatant was
then incubated with 5 mg of fusion protein immobilized on gluta-
thione agarose beads for 1 h at 4°C. The beads were washed twice
with lysis buffer and twice with phosphate-buffered saline. Bound
proteins were eluted by boiling in sample buffer (Laemmli, 1970)
and analyzed by Western blotting.
Fluorescence
For immunofluorescence, cells were fixed in 3.7% formaldehyde in
phosphate-buffered saline for 7 min at room temperature, and then
permeabilized with 0.5% triton X-100. As previously described,
epitope-tagged proteins were detected with KT3 (Schaller and Sasaki,
1997). Cells were stained with mAb 2A7 to detect exogenously ex-
pressed untagged FRNK. Primary mAbs were detected by staining
with a rhodamine-conjugated anti-mouse antibody (Jackson Immu-
noresearch Laboratories, West Grove, PA). For examination of GFP-
FAK, cells were plated onto glass coverslips and incubated overnight
at 37°C. The cells were then fixed and examined by microscopy. The
cells were visualized by using either a Leitz Orthoplan microscope or
Zeiss Axiophot microscope. Images were collected with a microMax 5
mHz cooled CCD camera (Princeton Instruments, Monmouth Junc-
tion, NJ) and MetaMorph imaging software (Universal Imaging Corp.,
West Chester, PA).
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RESULTS
Targeting Carboxy-Terminal Residues of FAK for
Mutagenesis
CAKb is an FAK-related PTK that also exhibits paxillin
binding and contains a focal adhesion-targeting sequence at
its C terminus (Salgia et al., 1996; Hiregowdara et al., 1997; Li
and Earp, 1997; Schaller and Sasaki, 1997; Xiong et al., 1998).
Because the C termini of FAK and CAKb are 61% identical,
conserved residues likely mediate these functions. The sec-
ondary structure of this region of FAK is predicted to be
a-helical and the a-helices are amphipathic in nature. Ala-
nine substitutions were made for a number of residues
conserved between FAK and CAKb (Figure 1). Furthermore,
these substitutions were designed to remove either charged
residues or hydrophobic residues from the surface of an
amphipathic a-helix. Oligonucleotide-directed mutagenesis
was used to generate seven mutants, each containing two or
three substitutions, and the mutants were identified by nu-
cleotide sequencing. Sequence analysis revealed that one of
the mutants contained an aspartic acid substitution for as-
paragine (at FAK residue 992) in addition to the two tar-
geted mutations. This mutation was introduced during the
mutagenesis reaction and not during subsequent amplifica-
Figure 1. Carboxy-terminal FAK Mutations. (A) Schematic illustration of full-length FAK is shown. (B) Schematic illustration of the FAT
sequence is shown. Bars underneath the schematic indicate the positions of four predicted a-helices in the FAT sequence, which are
designated 1–4. (C) Amino acid sequences of four regions of the FAT sequence of FAK are aligned with the corresponding sequences of
CAKb. The positions of the predicted a-helices are overlined and designated 1–4. Residues that are identical in FAK (upper sequence) and
CAKb (lower sequence) are shaded. The two boxed sequences in regions 1 and 4 are the vinculin homologous sequences of FAK that have
been designated paxillin-binding site 1 (PBS1) and paxillin-binding site 2 (PBS2), respectively. The open circles (V) below the sequences
denote point mutations in FAK that have been reported (Tachibana et al., 1995). Alanine residues have been substituted for the indicated FAK
residues to create FAKE949/K956/R963 (indicated by f), FAKV955/L962 (indicated by Œ), FAKE985/K989 (indicated by drops, ), FAKE983/N992D/D994
(indicated by »), FAKL995/L998 (indicated by ✚), FAKH1026/K1033 (indicated by v), and FAKL1028/L1035 (indicated by tilde signs ).
FAKE983/N992D/D994 contains an unintended mutation in addition to the alanine substitutions. Asparagine 992 is mutated to aspartic acid. This
mutation also is indicated by a filled diamond (l). These amino acids also were mutated in FRNK; the residue number in the corresponding
FRNK mutants is indicated in parentheses.
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tion of the sequence. The other variants had no alterations
other than the engineered alanine substitutions.
FAK Mutants Defective for Paxillin Binding
To assess paxillin binding, each mutant was expressed as a
GST fusion protein containing FAK codons 765-1052 (Shen et
al., 1998). The fusion proteins were immobilized on gluta-
thione agarose beads and incubated with CE cell lysates.
Bound paxillin was detected by Western blotting. As previ-
ously reported, fusion proteins containing wild-type FAK
sequences bound paxillin (Figure 2, lane 3). Binding was
specifically mediated by the FAK sequences because GST
alone, immobilized to glutathione beads, failed to associate
with paxillin (Figure 2, lane 2). In addition, a 50-kDa protein
that was recognized by the paxillin antibody also bound
GST-FAK. This is presumably the avian homolog of hydro-
gen peroxide-inducible clone 5 (Hic-5). GST-FAKE985/K989
bound paxillin as well as wild-type GST-FAK (Figure 2, lane
7) (note that the GST-FAK mutants are designated by using
the codon numbering of full-length FAK). Two other FAK
mutants, GST-FAKE949/K956/R963 and GST-FAKH1026/K1033,
also exhibited paxillin binding, although the ability of each
to associate with paxillin was slightly reduced relative to
wild-type GST-FAK (Figure 2, lanes 5 and 9). The other four
FAK mutants, GST-FAKV955/L962, GST-FAKE983/N992D/D994,
GST-FAKL995/L998, and GST-FAKL1028/L1035, were all com-
pletely defective for paxillin binding in vitro (Figure 2, lanes
4, 6, 8, and 10). The blot was stripped and reprobed with a
GST polyclonal antibody to verify that equal amounts of
each fusion protein were used in the experiment (Figure 2,
bottom). It is noteworthy that the altered residues in three of
these mutants lie outside the vinculin homologous se-
quences of FAK, which have been proposed to comprise the
paxillin-binding site (Tachibana et al., 1995).
Expression of FAK and FRNK Mutants in Avian and
Mammalian Cells
For expression in CE cells, the mutants were rescued into the
full-length FAK cDNA containing a carboxy-terminal
epitope tag. Although the presence of the tag perturbs the
ability of an otherwise wild-type FAK protein to bind pax-
illin (Hildebrand et al., 1995), tagged wild-type FAK cor-
rectly localizes to focal adhesions and its phosphotyrosine
content is regulated by cell adhesion (Schaller et al., 1993;
Hildebrand et al., 1995; Shen and Schaller, 1999). Each con-
struct was subcloned into the RCAS A avian replication
competent retroviral vector and introduced into CE cells by
transfection. Expression was initially examined by Western
blot analysis of whole cell lysates by using an FAK poly-
clonal antiserum (BC4) and the KT3 mAb, which recognizes
the epitope tag. KT3 did not recognize any proteins in CE
cells transfected with the empty RCAS vector (Figure 3A,
top, lane 1). In contrast, a 125-kDa reactive species was
detected by KT3 in lysates from each of the wild-type and
mutant FAK-transfected cells (Figure 3A, top). A similar level
of each protein was detected, except for FAKE983/N992D/D994,
which was very poorly expressed (our unpublished obser-
vations). It is not clear why this construct could not be
expressed because FRNK and GFP-FAK constructs contain-
ing the same point mutations were expressed to levels
similar to wild type. The low level of expression of
FAKE983/N992D/D994 precluded its further analysis. Lysates
also were probed with BC4, a polyclonal FAK antiserum
(Figure 3A, middle). Each of the mutant proteins was rec-
ognized by BC4 and was dramatically overexpressed rela-
tive to endogenous wild-type FAK, which was undetectable
at this exposure. Western blots of each of the mutants also
were probed with the 2A7 FAK mAb. Although wild-type
FAK and most of the mutants were recognized by 2A7,
FAKL995/L998 and FAKL1028/L1035 were not detected in this
Western blot (Figure 3A, bottom, lanes 6 and 8). This result
represented a specific failure of 2A7 to bind to these two
mutants because parallel Western blots demonstrate that
these proteins are recognized by both KT3 and BC4 (Figure
3A, top and middle). To examine tyrosine phosphorylation
of the mutants, each was immunoprecipitated by using KT3
and analyzed by Western blotting for phosphotyrosine. Both
the exogenous wild-type FAK and each of the mutants con-
tained phosphotyrosine (Figure 3B, top). Two of the mu-
tants, FAKL995/L998 and FAKL1028/L1035, exhibited a reduc-
tion in the level of tyrosine phosphorylation (Figure 3B, top,
Figure 2. Paxillin-binding activity of FAK mutants. Each mutant
was expressed as a GST fusion protein and immobilized to gluta-
thione agarose beads. CE cell lysate was precleared by incubation
with GST alone immobilized to glutathione agarose beads. The
cleared lysates were then incubated with GST (lane 2), GST-Hter
(wild type) (lane 3), GST-FAKV955/L962 (lane 4), GST-FAKE949/K956/R963
(lane 5), GST-FAKE983/N992D/D994 (lane 6), GST-FAKE985/K989 (lane
7), GST-FAKL995/L998 (lane 8), GST-FAKH1026/K1033 (lane 9), or GST-
FAKL1028/L1035 (lane 10). The beads were washed and bound paxillin
was detected by Western blotting (top). Twenty-five micrograms of
lysate was run as a control (lane 1). The paxillin band and a second
reactive protein that is presumably hydrogen peroxide-inducible
clone 5 are indicated by arrows. The blot was stripped and reprobed
with a GST antibody as loading control for the GST-FAK fusion
proteins (bottom).
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lanes 6 and 8). This reduction in tyrosine phosphorylation
was not due to differences in recovery of the proteins by
immunoprecipitation, as indicated in the control KT3 West-
ern blot (Figure 3B, bottom). Thus, most of the mutants were
efficiently expressed as full-length FAK constructs and were
tyrosine phosphorylated, although two mutants exhibited
reduced tyrosine phosphorylation.
The mutants also were rescued into a full-length FRNK
construct (lacking an epitope tag) for expression in CE cells.
Each was subcloned into the RCAS A vector and transfected
into CE cells. Lysates were analyzed by Western blotting
with BC4. The wild-type FRNK protein and each of the
mutants were expressed to high levels relative to the level of
endogenous FRNK (Figure 3C).
Wild-type FAK and two mutants that were defective for
paxillin binding, FAKV955/L962 and FAKE983/N992D/D994,
were engineered for expression in mammalian cells as GFP
fusion proteins. Using the pEGFP-C3 vector, the FAK se-
quences were fused in-frame and downstream of the GFP-
encoding sequences. The FAK sequences did not contain the
carboxy-terminal epitope tag. The resulting plasmids were
transiently transfected into 293 cells for expression. Lysates
were analyzed by Western blotting with BC4. Control trans-
fected cells, as well as cells transfected with the GFP-FAK
constructs, expressed the 125-kDa endogenous wild-type
FAK protein (Figure 3D, lane 1). In addition to this protein,
cells transfected with the plasmids encoding GFP-FAK fu-
sion proteins contained a protein of 152-kDa that was de-
tected with BC4 (Figure 3D, lanes 2–4). This protein was not
expressed in control-transfected cells and migrated with the
predicted mobility of the GFP-FAK fusion protein. Although
cells transfected with the GFP-FAK constructs appeared to
contain higher levels of endogenous FAK, this was likely a
degradation product of the full-length GFP-FAK proteins
because a number of other minor BC4 reactive species also
were present in these lysates. Each of the GFP-FAK con-
structs was expressed to a similar level.
Subcellular Localization of Mutant Proteins
The subcellular localization of the epitope-tagged, FAK mu-
tants in CE cells was determined by immunofluorescence
Figure 3. Expression of FAK, FRNK, and GFP-FAK constructs. (A) Twenty-five micrograms of lysate from control CE cells (lane 1), or CE
cells expressing epitope-tagged FAK (lane 2), FAKE949/K956/R963 (lane 3), FAKV955/L962 (lane 4), FAKE985/K989 (lane 5), FAKL995/L998 (lane 6),
FAKH1026/K1033 (lane 7), or FAKL1028/L1035 (lane 8) was analyzed by Western blotting with KT3 (top), BC4 (middle), or 2A7 (bottom). (B) FAK
was immunoprecipitated from lysates from control CE cells (lane 1), or CE cells expressing epitope-tagged FAK (lane 2), FAKE949/K956/R963
(lane 3), FAKV955/L962 (lane 4), FAKE985/K989 (lane 5), FAKL995/L998 (lane 6), FAKH1026/K1033 (lane 7), or FAKL1028/L1035 (lane 8). The immune
complexes were blotted for phosphotyrosine (top). The blot was stripped and reprobed for the exogenous FAK proteins with KT3 (bottom).
(C) Twenty-five micrograms of lysate from control CE cells (lane 1), or CE cells expressing FRNK (lane 2), FRNKE289/N298D/D300 (lane 3),
FRNKV261/L268 (lane 4), FRNKE291/K295 (lane 5), FRNKH332/K339 (lane 6), FRNKL334/L341 (lane 7), or FRNKE255/K262/R269 (lane 8) was analyzed
by Western blotting with BC4. (D) Twenty-five micrograms of lysate from control 293 cells (lane 1) or 293 cells transfected with a plasmid
encoding GFP-FAK (lane 4), GFP-FAKE983/N992D/D994 (lane 2), or GFP-FAKV955/L962 (lane 3) was Western blotted by using BC4.
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with the KT3 mAb. As previously described, control CE cells
that do not express the epitope tag exhibit a very diffuse,
pale staining with KT3 (Figure 4A). In contrast, cells express-
ing epitope-tagged FAK exhibit very prominent focal adhe-
sion staining with the KT3 antibody (Figure 4B). Most of the
mutants analyzed targeted to focal adhesions. Like wild-
type, epitope-tagged FAK, mutants FAKE949/K956/R963 (Fig-
ure 4C), FAKE985/K989 (Figure 4E), and FAKH1026/K1033 (Fig-
ure 4G) exhibited prominent focal adhesion localization.
FAKV955/L962 also exhibited focal adhesion staining, al-
though the fluorescence intensity was lower (Figure 4D). In
contrast, FAKL995/L998 (Figure 4F) and FAKL1028/L1033 (Fig-
ure 4H) exclusively exhibited a diffuse cytoplasmic staining
pattern with no evidence of specific focal adhesion staining.
The subcellular localization of untagged FRNK mutants in
CE cells was determined by immunofluorescence with mAb
2A7. With the staining conditions used, endogenous wild-
type FAK and FRNK exhibited a very pale focal adhesion-
staining pattern in control cells transfected with the empty
RCAS vector (Figure 5A). Cells expressing exogenous wild-
type FRNK were brightly stained with very prominent focal
adhesion staining (Figure 5B). Thus, the subcellular localiza-
tion of the exogenously expressed protein was readily dis-
tinguishable from endogenous protein based upon the in-
tensity of the signal. Mutants FRNKE291/K295 (Figure 5C),
FRNKE289/N298D/D300 (Figure 5D), FRNKV261/L268 (Figure
5E), and FRNKH332/K339 (Figure 5F) all exhibited a very
distinct focal adhesion-staining pattern. FRNKE255/K262/R269
also exhibited focal adhesion staining (our unpublished ob-
servations). The localization of FRNKL334/L341 was not de-
termined in this analysis because the mutations eliminated
recognition by mAb 2A7.
The subcellular localization of GFP-FAK was examined in
transiently transfected NIH 3T3 cells. Cells expressing a
GFP-wild–type FAK fusion protein exhibited bright cellu-
lar/cytoplasmic staining as well as focal adhesion localiza-
tion (Figure 6A). The subcellular localization of two mutants
that were defective for paxillin binding in vitro was deter-
mined. Both GFP-FAKV955/L962 (Figure 6B) and GFP-
FAKE983/N992/D/D994 (Figure 6C) exhibited the same local-
ization pattern as wild-type FAK. Thus, these mutants can
correctly localize to focal adhesions despite their inability to
bind paxillin in vitro.
GFP-FAK Mutants Fail to Bind Paxillin In Vivo
To further examine the ability of FAK mutants to associate with
paxillin in vivo, GFP-FAK fusion proteins were expressed tran-
siently in 293 cells. GFP-FAK was immunoprecipitated from
cell lysates by using BC4 and the immune complexes were
analyzed by Western blotting for paxillin. A small amount of
paxillin was coimmunoprecipitated with endogenous wild-
type FAK from 293 cells (Figure 7, top, lane 1). However, a
significantly increased level of paxillin was detected in im-
mune complexes from cells transfected with GFP-wild–type
FAK, demonstrating that the exogenously expressed fusion
protein bound paxillin in vivo (Figure 7, top, lane 2). In con-
trast, the amount of paxillin coimmunoprecipitated from cells
transfected with GFP-FAKV955/L962 (Figure 7, top, lane 3) or
GFP-FAKE983/N992/D/D994 (Figure 7, top, lane 4) was no greater
than the amount of paxillin coimmunoprecipitated with en-
dogenous FAK from control-transfected cells. Thus, these two
mutants failed to associate with paxillin in vivo. The blot was
stripped and reprobed with BC4 to demonstrate equal immu-
noprecipitation of each of the GFP fusion proteins (Figure 7,
bottom). Endogenous FAK was not detected in the exposure
shown in Figure 7. These in vivo-binding data corroborate the
results of the in vitro paxillin-binding assay, confirming that
these two FAK mutants are defective for paxillin binding.
Cell Adhesion-Dependent Tyrosine Phosphorylation
of FAK Mutants
The major stimulus regulating tyrosine phosphorylation of
FAK is cell adhesion. To establish whether the FAK mutants
were regulated by cell adhesion, CE cells expressing each
were held in suspension or plated onto poly-l-lysine– or
fibronectin–coated dishes and incubated for 30 min at 37°C
before lysis. Exogenously expressed FAK was immunopre-
cipitated by using mAb KT3 and the immune complexes
analyzed by Western blotting for phosphotyrosine. Wild-
type tagged FAK was phosphorylated in cells in culture. The
phosphotyrosine content was dramatically reduced when
cells were held in suspension. It became tyrosine phosphor-
ylated when cells adhered to fibronectin-coated surfaces, but
was poorly phosphorylated in response to adhesion to poly-
l-lysine (Figure 8A & B, top, lanes 1–4). FAKE985/K989 re-
sponded very similarly to wild-type FAK (Figure 8A, top,
lanes 13–16). Mutants FAKE949/K956/R963 (Figure 8A, top,
lanes 5–8), FAKH1026/K1033 (Figure 8B, top, lanes 9–12), and
FAKV955/L962 (Figure 8A, top, lanes 9–12) also exhibited cell
adhesion-dependent tyrosine phosphorylation. Differences
in the level of expression of the mutants in this experiment
make it difficult to compare relative levels of phosphoty-
rosine between mutants. However, it is apparent that
FAKE949/K956/R963, FAKH1026/K1033, and FAKV955/L962 con-
tain elevated levels of phosphotyrosine when cells are plated
onto fibronectin relative to the poly-l-lysine–plated controls.
Only two mutants, FAKL995/L998 and FAKL1028/L1035, were
defective for cell adhesion-dependent tyrosine phosphory-
lation. FAKL995/L998 (Figure 8B, top, lanes 5–8) and
FAKL1028/L1035 (Figure 8B, top, lanes 13–16) were tyrosine
phosphorylated in cells growing in culture. The phosphoty-
rosine content of each mutant was reduced when cells were
held in suspension in serum-free medium. However, neither
mutant became tyrosine phosphorylated when cells were
plated on fibronectin. The phosphotyrosine level of each was
similar in cells adhered to fibronectin or to poly-l-lysine–
coated dishes for 30 min. These two mutants also exhibit a
defect in localization, reinforcing the hypothesis that focal
adhesion targeting is essential for cell adhesion-dependent
regulation of FAK.
Mutants Exhibit Defects in Induction of Paxillin
Phosphorylation
Tyrosine phosphorylation of paxillin can be induced in an
FAK-dependent manner. Pharmacological inhibition of pro-
tein tyrosine phosphatases in FAK overexpressing CE cells
leads to enhanced phosphorylation of paxillin (Schaller and
Parsons, 1995; Schaller and Sasaki, 1997; Shen and Schaller,
1999). Each of the FAK mutants was examined to determine
whether its ability to induce paxillin phosphorylation was
impaired. CE cells were left untreated or treated with 2 mM
pervanadate for 30 min before lysis. Paxillin was immuno-
precipitated and analyzed by Western blotting for phospho-
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Figure 4. Subcellular localization of
epitope-tagged FAK constructs. Control
CE cells (A), or CE cells expressing
epitope-tagged FAK (B), FAKE949/K956/R963
(C), FAKV955/L962 (D), FAKE985/K989 (E),
FAKL995/L998 (F), FAKH1026/K1033 (G), or
FAKL1028/L1035 (H) were grown on glass
coverslips. The cells were fixed, permeabil-
ized, and stained with mAb KT3. The an-
tibody was detected with rhodamine-
conjugated anti-mouse IgG antibody.
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tyrosine. Under these conditions, pervanadate treatment did
not alter the phosphotyrosine content of paxillin in CE cells
(Figure 9, A and B, top, lanes 1 and 2). In contrast, pervana-
date induced a very dramatic increase in tyrosine phosphor-
ylation of paxillin in CE cells overexpressing wild-type,
epitope-tagged FAK (Figure 9, A and B, top, lanes 3 and 4).
Similarly, paxillin phosphorylation was enhanced upon per-
vanadate treatment of CE cells expressing FAKE985/K989,
although the response was not as robust (Figure 9A, top,
lanes 9 and 10). All of the other mutants exhibited a dramat-
ically weaker induction of paxillin phosphorylation upon
pervanadate treatment (Figure 9, A and C, top). Two mu-
Figure 5. Subcellular localization of FRNK mutants. Control CE cells (A), or CE cells expressing FRNK (B), FRNKE291/K295 (C), FRNKE289/
N298D/D300 (D), FRNKV261/L268 (E), or FRNKH332/K339 (F) were plated on glass coverslips. The cells were fixed, permeabilized, and stained with
mAb 2A7. The mAb was detected with rhodamine-labeled anti-mouse IgG antibody.
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tants that fail to target to focal adhesions, FAKL995/L998 and
FAKL1028/L1035, did induce a small increase in tyrosine phos-
phorylation of paxillin (Figure 9C, lanes 5, 6, 9, and 10).
However, the level of tyrosine phosphorylation of paxillin
induced by these mutants was very low relative to the level
of phosphorylation induced by wild-type FAK (Figure 9C,
lanes 3 and 4). The reduction in tyrosine phosphorylation of
paxillin was not due to differential recovery of paxillin by
immunoprecipitation (Figure 9, A and C, bottom) or due to
differences in level of expression of the mutant FAK proteins
(Figure 9, B and D). This result demonstrates that the induc-
tion of tyrosine phosphorylation of paxillin by FAK in this
system does not strictly correlate with the localization of
FAK to focal adhesions. Although focal adhesion targeting is
important for efficient induction of paxillin phosphorylation,
some of the mutants correctly localize to focal adhesions yet
induce paxillin phosphorylation poorly.
Characterization of Dominant-Negative Activity of
FRNK Mutants
Overexpression of wild-type FRNK in CE cells blocks cell
spreading and tyrosine phosphorylation of endogenous
wild-type FAK, paxillin, and tensin (Richardson and Par-
sons, 1996). Each mutant was tested for its ability to inhibit
tyrosine phosphorylation of endogenous FAK in cells in
culture and after cell adhesion to fibronectin. Cells were
lysed and endogenous FAK was immunoprecipitated with
BC2, an antiserum recognizing the catalytic domain of FAK
and thus unable to recognize the exogenously expressed
FRNK (Richardson and Parsons, 1996). The immune com-
plexes were analyzed by Western blotting for phosphoty-
rosine. As previously described, expression of wild-type
FRNK reduced tyrosine phosphorylation on endogenous
FAK both in adherent cells growing in culture and in cells
plated onto fibronectin (Figure 10, A and C, top, lanes 4 and
6). Mutant FRNKE291/K295 behaved similarly to wild-type
FRNK, causing a reduction in tyrosine phosphorylation of
endogenous FAK in both adherent cells and in cells plated
onto fibronectin (Figure 10A, top, lanes 13 and 15). Three
Figure 6. Subcellular localization of GFP-FAK mutants. NIH 3T3 cells transiently expressing GFP-FAK (A), GFP- FAKV955/L962 (B), or
GFP-FAKE983/N992D/D994 (C) were grown on glass coverslips, fixed, and examined by fluorescent microscopy.
Figure 7. Association of paxillin with GFP-FAK. FAK was immuno-
precipitated with BC4 from lysates of control 293 cells (lane 1) or 293
cells transiently expressing GFP-FAK (lane 2), GFP-FAKV955/L962 (lane
3), or GFP-FAKE983/N992D/D994 (lane 4). Coimmunoprecipitated paxillin
was detected by Western blotting (top). The blot was stripped and
reprobed with BC4 to verify equal recovery of the GFP-FAK fusion
proteins by immunoprecipitation (bottom).
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mutants exhibited a partial defect in functioning as a dom-
inant-negative mutant in this assay. Expression of
FRNKE255/K262/R269, FRNKV261/268, or FRNKE289/N298D/D300
caused a reduction in the phosphotyrosine content of endog-
enous FAK, but the level of phosphotyrosine was higher
than in cells expressing wild-type FRNK (Figure 10A, top,
lanes 7–12 and Figure 10C, top, lanes 7–9). In contrast, two
mutants were completely defective for inhibiting tyrosine
phosphorylation of endogenous FAK. In cells expressing
FRNKH332/K339 or FRNKL334/L341 the level of tyrosine phos-
phorylation of endogenous FAK was similar to the levels
observed in control cells transfected with the empty RCAS
vector (Figure 10C, top, lanes 10–15). Differences in the level
of phosphotyrosine were not due to differences in recovery
of FAK by immunoprecipitation (Figure 10, A and C, bot-
tom). Control blots demonstrated that each of the FRNK
mutants was expressed to high levels (Figure 10, B and D).
Although these results demonstrate that targeting to focal
adhesions was required for FRNK to function as a domi-
nant-negative mutant, some mutants that targeted to focal
Figure 8. Cell adhesion-dependent regulation of
tyrosine phosphorylation mutants of FAK. CE cells
expressing wild-type, epitope-tagged FAK (A and
B, lanes 1–4) or FAKE949/K956/R963 (A, lanes 5–8),
FAKV955/L962 (A, lanes 9–12), FAKE985/K989 (A, lanes
13–16), FAKL995/L998 (B, lanes 5–8), FAKH1026/K1033
(B, lanes 9–12), or FAKL1028/L1035 (B, lanes 13–16)
were analyzed. Adherent cells (A) (lanes 1, 5, 9, and
13) or cells held in suspension (S) (lanes 2, 6, 10, and
14) or plated onto poly(l-lysine) (P) (lanes 3, 7, 11,
and 15) or fibronectin (F) (lanes 4, 8, 12, and 16) were
lysed. Exogenous FAK was immunoprecipitated
with KT3 and Western blotted for phosphotyrosine
(tops). The blot was stripped and reprobed with
BC4 (bottoms).
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adhesions were compromised in their ability to act in a
dominant-negative manner. This suggests that an additional
function is required for the dominant-negative activity of
FRNK.
DISCUSSION
In this report, we describe the generation of seven FAT
sequence mutants of FAK, each containing multiple alanine
substitutions. The results of this analysis are summarized in
Table 1. Four of these mutants exhibit severe defects in
paxillin binding. Two mutants fail to correctly localize to
focal adhesions and are not regulated by cell adhesion. Most
of the mutants are unable to induce tyrosine phosphoryla-
tion of paxillin to the same levels induced by wild-type FAK
in vivo. Several of the mutants are also defective at inhibit-
ing tyrosine phosphorylation of endogenous FAK when ex-
pressed as dominant-negative FRNK constructs. The find-
ings support the hypothesis that paxillin binding is
dispensable for focal adhesion targeting of FAK. Cell adhe-
sion-dependent regulation of FAK strictly correlated with
localization to focal adhesions. However, focal adhesion
targeting is not sufficient for the induction of paxillin phos-
phorylation by FAK or for the inhibition of endogenous FAK
signaling by FRNK.
Both FAK and vinculin bind to the amino-terminal half
of paxillin (Turner and Miller, 1994). The paxillin-binding
site in vinculin has been defined and this region exhibits
sequence homology with two discontinuous sequences
within the FAT sequence of FAK (Wood et al., 1994; Tachi-
Figure 9. Induction of tyrosine phosphorylation of paxillin by FAK mutants. (A and C) Control CE cells (lanes 1 and 2) or CE cells
expressing wild-type, epitope-tagged FAK (lanes 3 and 4) or FAKE949/K956/R963 (A, lanes 5 and 6), FAKV955/L962 (A, lanes 7 and 8),
FAKE985/K989 (A, lanes 9 and 10), FAKL995/L998 (C, lanes 5 and 6), FAKH1026/K1033 (C, lanes 7 and 8), or FAKL1028/L1035 (C, lanes 9 and 10) were
left untreated (odd lanes) or treated with pervanadate (even lanes). The cells were lysed and paxillin was immunoprecipitated and Western
blotted for phosphotyrosine (A and C, top). The blot was striped and reprobed for paxillin (A and C, bottom). (B and D), Twenty-five
micrograms of cell lysate was analyzed for FAK expression by Western blotting with BC4.
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bana et al., 1995). Point mutations introduced into the
vinculin homologous sequences in FAK perturbed paxil-
lin binding, reinforcing the hypothesis that these se-
quences mediate binding to paxillin (Tachibana et al.,
1995). However, in this report several other paxillin-bind-
ing defective mutants that contain lesions outside of the
region of vinculin homology have been identified
(FAKV955/L962, FAKE/983/N992/D300, and FAKL995/L998).
Therefore, the paxillin-binding region of FAK extends
beyond this region of homology with vinculin. This find-
ing is not surprising given the results of a deletion anal-
ysis of paxillin. Although both FAK and vinculin were
demonstrated to bind to the LD2 motif of paxillin, FAK,
but not vinculin, was shown to bind to a second LD motif
(LD3) in paxillin (Brown et al., 1996). One simple model of
interaction is that the vinculin homologous sequences in
FAK bind to LD2 and FAK residues outside of the se-
quences of vinculin homology interact with LD3. One
prediction of this model is that specific point mutations in
FAK would disrupt binding to LD3 and leave binding to
LD2 unperturbed. However, the mutants described in this
report exhibit profound defects in binding to both the LD2
and LD3 motifs of paxillin (Thomas et al., 1999). Therefore,
this simple model of interaction is incorrect.
There are two prevailing models for focal adhesion tar-
geting of FAK. First, because a number of FAK mutants that
do not bind paxillin fail to target to focal adhesions, paxillin
has been proposed as the binding partner that targets FAK
to focal adhesions (Tachibana et al., 1995). Second, talin has
been proposed as the binding partner that targets FAK to
focal adhesions (Zheng et al., 1998). The first model is not
strictly correct because a carboxy-terminal, epitope-tagged
Figure 10. Inhibition of tyrosine phosphorylation of endogenous FAK by FRNK mutants. (A and C) Control CE cells (lanes 1–3) or CE cells
expressing wild-type FRNK (lanes 4–6) or FRNKE255/K262/R269 (A, lanes 7–9), FRNKV261/L268 (A, lanes 10–12), FRNKE291/K295 (A, lanes 13–15),
FRNKE289/N298D/D300 (C, lanes 7–9), FRNKH332/K339 (C, lanes 10–12), or FRNKL334/L341 (C, lanes 13–15) were analyzed. Adherent cells (A) (A
and C, lanes 1, 4, 7, 10, and 13) or cells held in suspension (S) (lanes 2, 5, 8, 11, and 14) or cells plated onto fibronectin (F) (lanes 3, 6, 9, 12,
and 15) were lysed and endogenous FAK was immunoprecipitated by using BC2. The immune complexes were analyzed by Western blotting
for phosphotyrosine (A and C, top). The blots were stripped and reprobed for FAK (A and C, bottom). (B and D) Twenty-five micrograms
of cell lysate was analyzed for FRNK expression by Western blotting with BC4.
FAT Sequence Mutants of FAK
Vol. 11, September 2000 3259
FAK variant fails to bind paxillin yet still localizes to focal
adhesions (Schaller et al., 1993; Hildebrand et al., 1995).
Furthermore, two mutants described in this report,
FAKV955/L962 and FAKE983/N992D/D994, fail to associate
with paxillin in vitro and in vivo but correctly localize to
focal adhesions. Recently, an additional analysis of the
L1034S FAK mutant (equivalent to our L1035 mutant; the
discrepancy in residue number reflects a species differ-
ence between avian and murine FAK) has been reported
(Sieg et al., 1999). This mutation disrupts paxillin binding,
but does not perturb the localization of FAK to focal
adhesions. Interestingly, this same mutation disrupts tar-
geting of a GST-FRNK fusion protein and FRNK to focal
adhesions, suggesting that focal adhesion targeting of
FAK and FRNK might occur via distinct mechanisms
(Tachibana et al., 1995; Sieg et al., 1999). It is not obvious
why two proteins with identical primary structure would
use different mechanisms to achieve the same end, i.e.,
target to focal adhesions. From our analysis FAKL1028/
L1035 did not target to focal adhesions, perhaps suggesting
that mutation of leucine 1028 was the critical alteration
that ablates focal adhesion-targeting activity.
Clearly, the results of these analyses provide compelling
evidence that paxillin binding is dispensable for focal adhe-
sion targeting of FAK. However, examination of all FAK
mutants that fail to target to focal adhesions reveals that
each is defective for paxillin binding (Hildebrand et al., 1995;
Tachibana et al., 1995). Thus, it is possible that there are two
targeting mechanisms of FAK, one paxillin dependent and
the other paxillin independent. Given this scenario, FAK
mutants that fail to target to focal adhesions would be
defective for paxillin binding and defective for engagement
with the paxillin-independent mechanism of targeting. One
candidate-binding partner for this latter mechanism of tar-
geting is obviously talin. We have been unable to evaluate
this hypothesis because we have been unable to consistently
demonstrate an interaction between wild-type FAK and
talin by coimmunoprecipitation or in in vitro-binding assays
with GST fusion proteins. Perhaps this is a low-affinity in-
teraction that cannot be detected under the lysis conditions
used. Alternatively, FAK may target to focal adhesions via
an undiscovered interaction.
Most of the mutants analyzed exhibited cell adhesion-
dependent tyrosine phosphorylation. The two exceptions
were FAKL995/L998 and FAKL1028/L1035, which also failed to
localize to focal adhesions. This finding corroborates previ-
ous findings that correct localization is a requirement for cell
adhesion-dependent regulation of FAK (Shen and Schaller,
1999). Each of the mutants that targeted to focal adhesions
exhibited cell adhesion-dependent tyrosine phosphoryla-
tion. Recall that these constructs contain a carboxy-terminal
epitope tag that ablates paxillin-binding activity. Therefore,
cell adhesion-dependent tyrosine phosphorylation of FAK is
independent of paxillin binding.
Two of the mutants that failed to target to focal adhesions
induced very low levels of tyrosine phosphorylation of pax-
illin. There are a number of possible explanations for this
observation. Perhaps these mutants induce tyrosine phos-
phorylation of a pool of paxillin that is not focal adhesion
localized. Alternatively, the FAK mutants may stimulate a
signaling pathway that indirectly results in tyrosine phos-
phorylation of paxillin in focal adhesions, e.g., via activation
of Src. Regardless of the mechanism of paxillin phosphory-
lation by these mutants, the induction of tyrosine phosphor-
ylation is very weak relative to the induction of paxillin
phosphorylation by wild-type FAK. Thus, focal adhesion
targeting was a prerequisite for efficiently inducing tyrosine
phosphorylation of paxillin. However, it was not sufficient
to induce paxillin phosphorylation because several mutants
localized to focal adhesions but only weakly induced paxil-
lin phosphorylation. This observation was surprising be-
cause we have described a FAK/vinculin chimera in which
the FAT sequence of FAK is replaced with the amino-termi-
nal focal adhesion targeting sequence of vinculin. This con-
struct targets to focal adhesions and can induce tyrosine
phosphorylation of paxillin in vanadate-treated CE cells,
suggesting that colocalization of the catalytic domain of
FAK with paxillin was sufficient to induce tyrosine phos-
phorylation of paxillin (Shen and Schaller, 1999). One hy-
pothesis that explains these observations is that FAK and
paxillin may need to colocalize in focal adhesions in a spe-
cific spatial arrangement for FAK-dependent tyrosine phos-
phorylation of paxillin. Presumably, the FAK/vinculin chi-
mera can mimic the required organization between wild-
Table 1. Summary of properties of FAK and FRNK mutants
















FAK FRNK 111 1 1 1 1 1 111 11
E949/K956/R963 E255/K262/R269 11 1 n.d. 1 n.d. 1 1 1
V955/L962 V261/L268 2 1 1 1 2 1 1 1
E985/K989 E291/K295 111 1 n.d. 1 n.d. 1 111 11
E983/N992D/D994 E289/N298D/D300 2 n.d. 1 1 2 n.d. n.d. 1
L995/L998 2 2 2 n.d. n.d. n.d. 2 2 n.d.
H1026/K1033 H332/K339 11 1 n.d. 1 n.d. 1 2 2
L1028/L1035 L334/L341 2 2 n.d. n.d. n.d. 2 2 2
n.d., not determined.
a Paxillin-binding activity of GST-FAK fusion proteins in vitro.
b Paxillin-binding activity of GFP-FAK fusion proteins in vivo.
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type FAK and paxillin within focal adhesions, whereas some
FAK mutants cannot. It may be noteworthy that the vinculin
sequences in the FAK/vinculin chimera contain a binding
site for talin (Gilmore et al., 1992). Our results also demon-
strate that tyrosine phosphorylation of paxillin by exog-
enously expressed FAK was not dependent upon physical
association with paxillin because the FAK constructs were
all carboxy-terminally epitope tagged and unable to bind
paxillin. This result is corroborated by analysis of a paxillin
mutant that is defective for FAK binding. This mutant shows
a partial reduction in tyrosine phosphorylation relative to
wild-type paxillin, suggesting that tyrosine phosphorylation
is partially dependent and partially independent of FAK
binding (Thomas et al., 1999). Although paxillin binding is
dispensable for the induction of paxillin phosphorylation by
FAK, these findings suggest that there is a second require-
ment in addition to focal adhesion targeting of FAK.
FRNK has been used as a dominant-negative mutant to
block biochemical signaling via FAK and to inhibit cell
spreading and motility, two biological processes controlled
by FAK (Gilmore and Romer, 1996; Richardson and Parsons,
1996). To function as a dominant-negative mutant, FRNK
must localize to focal adhesions because FRNKL334/L341 does
not inhibit tyrosine phosphorylation of endogenous FAK
when expressed in CE cells. This finding is consistent with
the observation that a FRNK mutant (L1034S) that fails to
target to focal adhesions cannot impair cell motility (Sieg et
al., 1999). However, targeting to focal adhesions is not suf-
ficient for FRNK to block FAK signaling because FRNKH332/
K339 correctly localizes to focal adhesions, yet does not cause
a reduction in tyrosine phosphorylation of endogenous
FAK. Similarly, an epitope-tagged variant of FRNK that
localizes to focal adhesions is also ineffective as a dominant-
negative mutant (Richardson et al., 1997). Because this vari-
ant fails to bind paxillin, it was suggested that paxillin
binding was a prerequisite for the dominant-negative activ-
ity of FRNK. However, the dominant-negative activity of the
mutants reported herein does not correlate with paxillin-
binding activity. These observations suggest that, in addi-
tion to focal adhesion targeting and paxillin binding, there
are other requirements for the dominant-negative activity of
FRNK.
Paxillin binding was previously proposed as the mecha-
nism for focal adhesion targeting of FAK and as an essential
feature for the dominant-negative function of FRNK. Al-
though our results do not strictly exclude a role for paxillin
binding in these functions, they clearly demonstrate a pax-
illin-independent mechanism of focal adhesion targeting for
FAK and suggest that paxillin is not the sole target for
FRNK-dependent inhibition of FAK. Elucidation of FAK
targeting and signaling clearly requires the identification of
the FAT sequence-binding partners mediating these func-
tions.
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